AstraZeneca / 阿斯利康

AstraZeneca / 阿斯利康 appears in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 as one of the multinational pharma companies buying or licensing Chinese biotech assets. The episode points to AstraZeneca’s acquisition of a Chinese CAR-T company around late 2023 as an early marker for the 2024 pattern of “bottom fishing” Chinese pipelines.

The source uses AstraZeneca as a transaction signal, not as a full strategic profile. Its role is to show that MNCs may treat depressed Chinese biotech valuations as an opportunity when their own pipeline pressure is rising.

Connections

• China Biotech Asset Repricing - main source concept around cross-border asset buying.
• CAR-T Cell Therapy and Solid Tumor CAR-T Constraints - cell-therapy context behind the acquisition example.
• Multinational Pharma Patent-Cliff Anxiety - broader reason big pharma is willing to move quickly.